PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

Gilead ...

【吉利德中国回应裁员：正在进一步调整资源 为长效HIV新药等近期 上市 的产品做准备】2024年年底至2025年3月，跨国药企 吉利德科学 （ Gilead Sciences ）分别在西雅图办事处、 加州 总部进行裁员，并宣布2025年中结束运营其细胞治疗子公司Kite Pharma在 费城 的工厂。日前， 吉利德 ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) following the success of a Phase I study. The Phase I ...

Gilead Sciences recently experienced a significant ... highlighted by successful data presentations at CROI 2025. The approval of lenacapavir for multi-drug resistant HIV and its promising trial ...

On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir. Lenacapavir is a novel, once-yearly injectable HIV-1 capsid inhibitor ...

Gilead Sciences. “Once-yearly lenacapavir, if approved, could become an important new HIV prevention option that could help address PrEP adherence and persistence challenges for individuals who ...

Gilead Sciences (NasdaqGS:GILD) has been the center of investor activism, facing several shareholder proposals, including the ...